ClinicalTrials.gg
CompletedNCT02130999Updated Aug 22, 2016Results posted

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

A Phase 4 interventional study of tasimelteon 20 mg capsule and tasimelteon 2 mg I.V. in Non-24-Hour-Sleep-Wake Disorder, sponsored by Vanda Pharmaceuticals. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-22.

Sponsored by Vanda Pharmaceuticals · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Hetlioz™ (tasimelteon) is used in the treatment of Non-24-Hour-Sleep-Wake Disorder (Non-24). Non-24 is very common in people who are totally blind because light can not reset their body clock. This causes the internal sleep-wake cycle to be out of sync with the 24-hour day-night. Non-24 is a serious, chronic circadian rhythm disorder in the blind that causes nighttime sleep problems and a wide range of daytime difficulties, including an overwhelming urge to nap.

Tasimelteon will be given in two ways; orally (by mouth) as a 20 mg capsule and intravenously (I.V.) by infusion through a catheter (not an injection) into a vein. The oral administration is approved by the FDA. The I.V. administration is considered investigational as it has not been approved by the FDA. This will be the first time tasimelteon will be given to humans by intravenous (I.V.) injection.

The purposes of this research study are to:

  • assess how quickly a single 20 mg oral dose of tasimelteon is absorbed into the body;
  • evaluate the single-dose pharmacokinetics of tasimelteon after a single 20 mg oral dose and after a single 2 mg I.V. dose;
  • evaluate the single-dose pharmacokinetics of tasimelteon metabolites after a single 20 mg oral dose and after a single 2 mg I.V. dose;
  • evaluate the safety and tolerability of a single 20 mg oral dose of tasimelteon; and
  • evaluate the safety and tolerability of a single 2 mg I.V. dose of tasimelteon.

Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and eventually eliminated by the body. Pharmacokinetics is what the body does to the drug. Blood samples will be taken throughout the study for PK analysis.

02

Conditions studied

  • Non-24-Hour-Sleep-Wake Disorder

Keywords

  • Non-24
  • absolute bioavailability
  • tasimelteon
  • Hetlioz™
03

In context

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

This study's enrollment of 14 is below the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.

Browse Sleep Disorders, Circadian Rhythm studies →

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ages 18 - 55 years, inclusive;
  2. Non-smokers [abstinence from smoking for at least 6 months before the screening visit] and test negative for cotinine at screening and baseline;
  3. Subjects with (BMI) of ≥18 and ≤25 kg/m2 (BMI = weight (kg)/ [height (m)]2);
  4. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is , without menses for 6 months before screening), or females of using an acceptable method of for a period of 35 days before the first dosing, and females must have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam
  5. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

    1. Body temperature between 35.0-37.5 °C;
    2. Systolic blood pressure between 90-150 mmHg;
    3. Diastolic blood pressure between 50-95 mmHg;
    4. Pulse rate between 50-100 bpm.
  6. Ability and acceptance to provide written ;
  7. Willing and able to comply with study requirements and restrictions;
  8. Subjects must be in good health as determined by past medical history, physical examination, , clinical laboratory tests and urinalysis;

Exclusion criteria

Exclusion Criteria:

  1. History of recent (within six months) drug or alcohol abuse as defined in , Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated by the laboratory assays conducted during the Screening Visit or at Baseline;
  2. Any major surgery within three months of the first Baseline visit or any minor surgery within one month;
  3. History or current evidence of cardiovascular, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction or psychiatric disease judged by the Investigator to be ;
  4. Subjects who are currently considered a suicide risk, any subject who has ever made a suicide attempt, or those who are currently demonstrating active (within the past 6 months) suicidal ideation as deemed by the Columbia Suicide Severity Rating Scale (C-SSRS);
  5. Any condition requiring the regular use of medication except those listed in Section 8.2;
  6. Exposure to any drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of baseline
  7. Exposure (within 2 weeks of Day -1) to any over-the-counter medications including melatonin, dietary supplements and/or herbal remedies, except those listed on Section 8.2;
  8. Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 days preceding the Screening visit;
  9. History of intolerance and/or to tasimelteon, and/or drugs similar to tasimelteon including melatonin;
  10. Donation or loss of 400 mL or more of blood within one month prior to the Baseline Visit;
  11. Significant illness within the two weeks prior to Baseline;
  12. Pregnant or lactating females;
  13. History of porphyria or liver disease and/or positive for one or more of the following serological results:

    1. A positive antibody test (anti-HCV)
    2. A positive surface antigen (HBsAg)
    3. A positive test result
  14. Use of any food or beverage containing grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats for at least 2 weeks before the Baseline Visit until the end of the study;
  15. Inability to be venipunctured and/or tolerate venous access;
  16. Previous participation in a BMS-214778, VEC-162, or tasimelteon study;
  17. Subjects who are unable to read or speak English;
  18. Any other sound medical reason as determined by the clinical Investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Sequence A

    * Single oral dose of tasimelteon 20 mg on Day 1 * Single I.V. dose of tasimelteon 2 mg on Day 6

    Drug: tasimelteon 20 mg capsule · Drug: tasimelteon 2 mg I.V.

  • Experimental
    Sequence B

    * Single I.V. dose of tasimelteon 2 mg on Day 1 * Single oral dose of tasimelteon 20 mg on Day 6

    Drug: tasimelteon 20 mg capsule · Drug: tasimelteon 2 mg I.V.

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg

    The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

Secondary outcomes

  1. Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

    Cmax of tasimelteon will be compared when given orally or administered as an I.V.

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

  2. AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

    AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

  3. T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

    T1/2 of tasimelteon will be compared when given orally or administered as an I.V.

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours pos-dose

  4. Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

    CL of tasimelteon will be compared when given orally or administered as an I.V.

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

  5. Cmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon

    The mean +/- SD for the Cmax of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

  6. AUC(Inf) of Tasimelteon's Metabolites After a Single Oral and I.V. Dose

    The mean +/- SD for the AUC(inf) of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

  7. Metabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon

    Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.

    Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose

  8. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse event per treatment arm and overall.

    Time frame: From Baseline to End of Study; Day 5 (± 2 days).

Other outcomes

  1. Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.

    Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.

    Time frame: Baseline to End of Study Day 5 (± 2 days).

07

Results

Posted Jul 22, 2016

Participant flow

Participant flow — Overall Study
MilestoneSequence ASequence B
Started68
Completed68
Not completed00

Outcome measures

PrimaryAbsolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg

The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Geometric mean · Geometric Mean Ratio (%)
Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg
Geometric Mean Ratio (%)Absolute Bioavailability
Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg38.3 (26.9 to 54.3)
SecondaryCmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

Cmax of tasimelteon will be compared when given orally or administered as an I.V.

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Mean · ng/mL
Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
ng/mLOral (20 mg)IV (2 mg)
Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.260 ± 18982.2 ± 20.5
SecondaryAUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Mean · (h*ng/mL)
AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
(h*ng/mL)Oral (20 mg)IV (2 mg)
AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.358 ± 27171.6 ± 23.9
SecondaryT1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

T1/2 of tasimelteon will be compared when given orally or administered as an I.V.

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours pos-dose
Reported as:
Mean · hour
T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
hourOral (20 mg)IV (2 mg)
T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.1.06 ± 0.231.02 ± 0.23
SecondaryTotal Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.

CL of tasimelteon will be compared when given orally or administered as an I.V.

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Mean · (mL/min)
Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
(mL/min)Oral (20 mg)IV (2 mg)
Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.2241 ± 3592505 ± 135
SecondaryCmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon

The mean +/- SD for the Cmax of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Mean · ng/mL
Cmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon
ng/mLOral (20 mg)IV (2 mg)
M9303 ± 94.316.4 ± 6.16
M1153.2 ± 16.143.7 ± 1.25
M12113 ± 30.87.31 ± 2.49
M13370 ± 10529 ± 11.7
SecondaryAUC(Inf) of Tasimelteon's Metabolites After a Single Oral and I.V. Dose

The mean +/- SD for the AUC(inf) of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Mean · h*ng/mL
AUC(Inf) of Tasimelteon's Metabolites After a Single Oral and I.V. Dose
h*ng/mLOral (20 mg)IV (2 mg)
M9400 ± 13930.3 ± 10.3
M11125 ± 43.712.2 ± 4.40
M12619 ± 36443.8 ± 25.4
M13431 ± 15238.2 ± 13
SecondaryMetabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon

Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.

Time frame:
pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Reported as:
Mean · metabolite to parent AUC (inf) ratios
Metabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon
metabolite to parent AUC (inf) ratiosOral (20 mg)IV (2 mg)
M91.98 ± 2.650.39 ± 0.12
M110.51 ± 0.350.16 ± 0.03
M122.04 ± 0.930.54 ± 0.15
M131.72 ± 1.120.51 ± 0.14
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse event per treatment arm and overall.

Time frame:
From Baseline to End of Study; Day 5 (± 2 days).
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsTasimelteon 20mg OralTasimelteon 2mg IVAll Subjects
vomiting011
headache112
Somnolance101
Other pre-specifiedNumber of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.

Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.

Time frame:
Baseline to End of Study Day 5 (± 2 days).
Reported as:
Number · participants
Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.
participantsTasimelteon 20mg OralTasimelteon 2mg IVAll Subjects
Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tasimelteon 20mg Oral—0/14 (0%)2/14 (14.3%)
Tasimelteon 2mg IV—0/14 (0%)1/14 (7.1%)
All Subjects—0/14 (0%)3/14 (21.4%)
Most frequent other events
Most frequent other events
EventTasimelteon 20mg OralTasimelteon 2mg IVAll Subjects
headacheNervous system disorders1/141/142/14
sommolenceNervous system disorders1/140/141/14
vomitingGastrointestinal disorders0/141/141/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Number of Baseline Participants
Mean31.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall Number of Baseline Participants
Female7
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Number of Baseline Participants
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Number of Baseline Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White8
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Overall Number of Baseline Participants
United States14
Body Mass Index
Body Mass Index((kg/m^2))Overall Number of Baseline Participants
Mean22.8 ± 1.8
Weight
Weight((kg))Overall Number of Baseline Participants
Mean63.6 ± 8
Height
Height((cm))Overall Number of Baseline Participants
Mean166.6 ± 10.4
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2014
First posted
May 6, 2014
Start
May 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Jul 22, 2016
Last update
Aug 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02130999
Responsible party
Sponsor
First posted
May 6, 2014
Start date
May 2014
Primary completion
May 2014
Completion
May 2014
Results posted
Jul 22, 2016
Last update
Aug 22, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion